Arrowhead Pharmaceuticals (ARWR) Projected to Release Earnings on Thursday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is projected to post its Q4 2026 results after the market closes on Thursday, November 12th. Analysts expect Arrowhead Pharmaceuticals to announce earnings of ($1.52) per share and revenue of $61.18 million for the quarter. Individuals may visit the company’s upcoming Q4 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Arrowhead Pharmaceuticals Trading Down 15.3%

Shares of ARWR stock opened at $49.24 on Tuesday. Arrowhead Pharmaceuticals has a 12 month low of $37.06 and a 12 month high of $95.49. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. The business’s 50 day moving average is $66.19 and its two-hundred day moving average is $71.39. The company has a market cap of $6.94 billion, a PE ratio of -21.88 and a beta of 1.34.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, Director Adeoye Olukotun sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total value of $173,920.00. Following the sale, the director owned 31,600 shares of the company’s stock, valued at $2,747,936. This trade represents a 5.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Michael Perry sold 11,600 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the transaction, the director directly owned 111,459 shares in the company, valued at approximately $9,730,370.70. This represents a 9.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 3.60% of the company’s stock.

Analyst Upgrades and Downgrades

ARWR has been the subject of a number of analyst reports. Royal Bank Of Canada restated an “outperform” rating and issued a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 31st. B. Riley Financial raised their target price on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, August 17th. JPMorgan Chase & Co. lifted their target price on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Finally, Stifel Nicolaus began coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They set a “buy” rating and a $98.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $99.07.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues.

The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.

Founded in 1989 as Arrowhead Research Corporation, the company adopted the name Arrowhead Pharmaceuticals in 2015.